A pharmacovigilance study of rituximab-associated adverse events in immune-mediated kidney diseases and transplant-related kidney diseases
CONCLUSION: These findings highlight the importance of vigilant, personalized surveillance in patients with immune-mediated kidney diseases receiving prolonged rituximab therapy, particularly considering the potential risks of malignancies. Given the extended…
Suggested reading